BRPI0417123A - formulação de torsemide de liberação prolongada - Google Patents

formulação de torsemide de liberação prolongada

Info

Publication number
BRPI0417123A
BRPI0417123A BRPI0417123-3A BRPI0417123A BRPI0417123A BR PI0417123 A BRPI0417123 A BR PI0417123A BR PI0417123 A BRPI0417123 A BR PI0417123A BR PI0417123 A BRPI0417123 A BR PI0417123A
Authority
BR
Brazil
Prior art keywords
torsemide
present
certain embodiments
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0417123-3A
Other languages
English (en)
Inventor
Pradeep Sanghwi
Sara Ketsela
Thomas Scianscia
Joseph Jaworski
Original Assignee
Penwest Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceutical Co filed Critical Penwest Pharmaceutical Co
Publication of BRPI0417123A publication Critical patent/BRPI0417123A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

é objeto da invenção presente para prover uma liberação contralada dosagem oral forma para torsemide ou um sal farmacêuticamente aceitável deste. é um objeto adicional de certas incorporações da invenção presente para prover um método para preparar um bioavailable sustentou liberação dosagem oral forma para torsemide ou um sal farmacêuticamente aceitável deste. é objeto adicional de certas incorporações da invenção presente para prover um método de tratamento de edema via administração de torsemide ou um sal farmacêuticamente aceitável deste em uma liberação contralada dosagem oral forma para um paciente humano em falta de tal tratamento. é um objeto adicional de certas incorporações da invenção presente para prover uma liberação contralada oral diuretico dosagem forma que não tem um perfil desfavorável como uma absorção oral irregular e variado bioavailability. é um objeto adicional de certas incorporações da invenção presente para prover um método de tratamento de falha de coração congestivo (CHF) via administração de torsemide ou um sal farmacêuticamente aceitável deste em uma liberação contralada dosagem oral forma para um paciente humano em falta de tal tratamento. é um objeto adicional de certas incorporações da invenção presente para prover uma liberação contralada dosagem oral forma que é apropriada para prover, quando combinado com torsemide ou um sal farmacêuticamente aceitável deste, uma liberação contralada formulação que provê terapeutica sangue níveis efetivos do torsemide para tratar edema e/ou falha de coração congestivo, E.G., mais ou menos 12 para mais ou menos 24 horas
BRPI0417123-3A 2003-12-12 2004-12-10 formulação de torsemide de liberação prolongada BRPI0417123A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52913803P 2003-12-12 2003-12-12
PCT/US2004/041963 WO2005058286A1 (en) 2003-12-12 2004-12-10 Sustained release torsemide dosage forms

Publications (1)

Publication Number Publication Date
BRPI0417123A true BRPI0417123A (pt) 2007-08-21

Family

ID=34699943

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417123-3A BRPI0417123A (pt) 2003-12-12 2004-12-10 formulação de torsemide de liberação prolongada

Country Status (13)

Country Link
US (1) US20050169991A1 (pt)
EP (1) EP1691790A1 (pt)
JP (1) JP2007513975A (pt)
KR (1) KR20060103330A (pt)
CN (1) CN1929823A (pt)
AP (1) AP2006003650A0 (pt)
AU (1) AU2004299077A1 (pt)
BR (1) BRPI0417123A (pt)
CA (1) CA2548387A1 (pt)
EA (1) EA200600953A1 (pt)
IL (1) IL176222A0 (pt)
MX (1) MXPA06006677A (pt)
WO (1) WO2005058286A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
WO2006076191A2 (en) * 2005-01-10 2006-07-20 Elc Management Llc Discontinuous surface coating for particles
US7795316B1 (en) 2007-12-19 2010-09-14 Alcon Research, Ltd. Topical ophthalmic compositions containing tobramycin and dexamethasone
JP2011530529A (ja) * 2008-08-07 2011-12-22 アバントール パフォーマンス マテリアルズ， インコーポレイテッド ゴムおよび糖アルコールを含む徐放性組成物
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US20140212488A1 (en) * 2012-05-01 2014-07-31 Althera Life Sciences Llc Oral tablet formulation consisting of immediate release rosuvastatin and extended release metformin
US10463622B2 (en) * 2013-10-06 2019-11-05 Sarfez Pharmaceuticals, Inc. Treatments and formulations comprising Torsemide
US10154963B2 (en) * 2013-10-06 2018-12-18 Sarfez Pharmaceuticals, Inc. Controlled-release formulations comprising Torsemide
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
AU2017350852A1 (en) * 2016-10-25 2019-04-11 Trevi Therapeutics, Inc. Treatment of prurigo nodularis
JP7390695B2 (ja) * 2017-02-03 2023-12-04 株式会社東洋新薬 錠剤及び錠剤の製造方法
JP6893687B2 (ja) * 2017-06-20 2021-06-23 トーアエイヨー株式会社 口腔内崩壊錠
MX2022008554A (es) 2020-01-10 2022-08-10 Trevi Therapeutics Inc Metodos de administracion de nalbufina.
CN113750068A (zh) * 2021-10-28 2021-12-07 江苏睿实生物科技有限公司 一种托拉塞米片及其制备方法
CN116421572A (zh) * 2023-04-28 2023-07-14 黑龙江中医药大学 一种水飞蓟素固体分散体缓释片及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
WO2003084524A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs

Also Published As

Publication number Publication date
CA2548387A1 (en) 2005-06-30
KR20060103330A (ko) 2006-09-28
WO2005058286A1 (en) 2005-06-30
IL176222A0 (en) 2006-10-05
AP2006003650A0 (en) 2006-06-30
AU2004299077A1 (en) 2005-06-30
EA200600953A1 (ru) 2006-10-27
US20050169991A1 (en) 2005-08-04
EP1691790A1 (en) 2006-08-23
JP2007513975A (ja) 2007-05-31
MXPA06006677A (es) 2006-08-31
CN1929823A (zh) 2007-03-14

Similar Documents

Publication Publication Date Title
BRPI0417123A (pt) formulação de torsemide de liberação prolongada
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
BR0312128A (pt) Formulação, produto farmacêutico, embalagem de pressão. mdi, pulverizador nasal, processos para preparar um produto farmacêutico e uma formulação e métodos para profilaxia ou tratamento em um mamìfero tal como um humano, de condições para as quais a administração de um ou mais anti-histamìnico e/ou um ou mais esteróides é indicada e para tratamento de irritação do distúrbios do nariz ou do olho e de distúrbios das vias aéreas
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
BR0306919A (pt) Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
NZ600718A (en) Method of treating atrial fibrillation
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
NZ605469A (en) Nalbuphine-based formulations and uses thereof
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
JP2020500864A5 (pt)
MX2009006114A (es) Composiciones que comprenden carisoprodol y metodos de uso de las mismas.
WO2015024420A1 (zh) 局麻药止痛延时剂
EP4389218A3 (en) Composition for treating joint disease and kit containing same
NZ751972A (en) Treatment of prurigo nodularis
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2022026622A3 (en) Treatment of viral diseases
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]